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PREFACE 
 
Breast cancer is the most common cancer in women worldwide, with an incidence of 
approximately one million cases every year and is the main cause of cancer related 
deaths in women. Triple negative breast cancer is known to be aggressive; have a 
worse prognosis and is associated with lympho-vascular invasion, higher recurrence 
rate and metastasis. The reason behind this aggressiveness is not completely 
understood. Anaemia is common in breast cancer patients and may be a result of 
the disease process, complication of treatment or pre-existing co-morbidities. We 
would like to determine the prevalence and type of anaemia in patients with triple 
negative breast cancer at Charlotte Maxeke Johannesburg Academic Hospital. If 
anaemia is identified early and corrected, it will positively impact on the outcome in 
terms of a clinical perspective and quality of life. Hence I endeavoured to determine 
the type and prevalence of anaemia in triple negative breast cancer patients. The 
recommendation to create awareness of anaemia and the correction of anaemia in 
this group will make a significant change in the management plan of the patients. 
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ABSTRACT  
 
Background 
Breast cancer is the most common cancer in women worldwide, with an incidence of 
approximately one million cases every year and is the main cause of cancer related 
deaths in women [1-3]. Breast cancers which are considered to be aggressive are triple 
negative breast cancers [4].  Triple negative breast cancer is known to have a  worse 
prognosis and is associated with lympho-vascular invasion, higher recurrence rate and 
metastasis [4]. The reason behind this aggressiveness is not completely understood. 
Anaemia is common in breast cancer patients and may be a result of the disease 
process, complication of treatment or pre-existing co-morbidities [5-8]. Clinically 
significant anaemia is defined as a Haemoglobin level less than 10g/dL, and is 
accompanied by the symptoms and signs of anaemia such as fatigue, dizziness and 
pallor [9]. This degree of anaemia can result in a  delay of initiating therapy as well as 
delay to correct the anaemia before initiating treatment such as neoadjuvant 
chemotherapy and surgery [10]. Furthermore, patients with anaemia with an Hb<10g/dL 
are known to blunt response to chemotherapy and radiotherapy due to tissue hypoxia 
[6]. The aim of this study is to determine the prevalence and type of anaemia in patients 
with triple negative breast cancer at Charlotte Maxeke Johannesburg Academic 
Hospital.  
 
Aim 
 
To determine the prevalence and type of anaemia in patients with triple negative breast 
cancer at Charlotte Maxeke Johannesburg Academic Hospital.  
 XIII 
 
Objectives 
 
1. To study the demography of patients presenting with breast cancer. 
2. To determine the prevalence of triple negative breast cancer. 
3. To determine prevalence and type of anaemia in patients with breast cancer 
and whether this is affected by receptor status. 
 
Method 
 
This was a retrospective review of records of patients from the Breast and Endocrine 
Unit at Charlotte Maxeke Johannesburg Academic Hospital over 2002-2012 (11 year 
period). Once ethical approval was granted, data was obtained from the National 
Health Laboratory Services records of all breast cancer patients for the period 2002-
2012 (11 year period) at Charlotte Maxeke Johannesburg Academic Hospital. 
Patients demography, histological subtypes and profile was recorded as well as 
haemoglobin and mean corpuscular volume (Appendix 1).  
 
The data was recorded in Excel spreadsheets and the proportion of triple negative 
breast cancer patients with or without anaemia at the time of diagnosis (within 3 
months) was compared using the chi-squared statistical tests to determine if a 
correlation exists.   Age categories were expressed using the data sets of average 
(including standard deviation) and range. Gender was  calculated as percentages  
and expressed as a ratio.  
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 Results 
Records of 520 patients were found; of which 94 patients were excluded. The 
average age was 55± 13.3 years (range 18-91).  The female to male ratio was 109:1. 
Fifty two patients had triple negative breast cancer (TNBC) and 374 patients had 
receptor positive breast cancer (RPBC). Of these, only 246 patients had a 
haemoglobin level matched at time of diagnosis (within 3 months) that is 29 patients 
in the TNBC group and 217 patients in the RPBC group. Approximately 26% 
(65/246) of patients with haemoglobin level matched at time of diagnosis (within 3 
months) had anaemia at the time of presentation.  
Anaemia was found to be more significant and prevalent in the TNBC group as 
55.2% (16/29) of the TNBC group had anaemia whereas 22.6% (49/217) of the 
RPBC group patients were found to have anaemia at presentation. In the TNBC 
group, 16 of 29 patients had anaemia and microcytic and normocytic anaemia were 
equally common. Whereas, in the RPBC group, 49 of 217 patients had anaemia and 
normocytic anaemia was the most common i.e. 51% (25/49 patients).  
 
Conclusion 
Anaemia was found to be more common in patients with TNBC compared to RPBC. 
The predominant types of anaemia found in TNBC patients are microcytic and 
normocytic and may suggest different mechanisms. Within the TNBC group, 
microcytic and normocytic and macrocytic anaemia were 7/16 (43.75%); 7/16 
(43.75%); and 2/16 (12,5%) respectively. Whereas, within the RPBC group, 
microcytic and normocytic and macrocytic anaemia were 22(44,89%); 25 (51.02%) 
and 2 (0.4%) respectively.  
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CHAPTER 1 
1. Introduction  
Breast cancer is the most common cancer in women worldwide, with an incidence of 
approximately one million cases every year and is the main cause of cancer related 
deaths in women [1-3]. Triple negative breast cancers are known to be  aggressive 
[4].  Triple negative breast cancer is known to have a  worse prognosis and is 
associated with lympho-vascular invasion, higher recurrence rate and metastasis [4]. 
The reason behind this aggressiveness is not completely understood. Anaemia is 
common in breast cancer patients and may be a result of the disease process such 
as bone marrow infiltration, complication of treatment or pre-existing co-morbidities 
and as a result of iron metabolism and utilisation [5-8, 11].  Cytokine mediated 
systemic inflammatory response which occurs in cancer patients has been 
implicated to cause anaemia [11].  
Clinically significant anaemia is defined as a Haemoglobin level less than 10g/dL or 
when accompanied by the symptoms and signs such as fatigue, dizziness and pallor 
[9]. This degree of anaemia can result in a  delay of initiating therapy such as 
neoadjuvant chemotherapy and surgery [10]. Furthermore, patients with anaemia 
with an Hb<10g/dL is known to blunt response to chemotherapy and radiotherapy 
due to tissue hypoxia [6].  
The aim of this study was to determine the prevalence and type of anaemia in 
patients with triple negative breast cancer at Charlotte Maxeke Johannesburg 
Academic Hospital.  
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1.1. Literature Review  
 
Breast cancer is the most common cancer worldwide with an incidence of 
approximately one million cases ever year [1, 2]. It is the main cause of cancer 
related deaths in women, however the  incidence rates differ worldwide [3]. 
Prognostic factors include tumour size, histological grade and subtype, mitotic index 
of proliferation, lymph node status, hormone receptor status and lympho-vascular 
infiltration [12]. In South Africa data regarding incidence rates of breast cancer 
including triple negative breast cancer, risk assessment and symptomology remains 
under-reported.  
 
Triple negative breast cancer is defined as a breast malignancy with the absence of 
all of the following receptors: oestrogen, progesterone and human epidermal growth 
factor-2 [13, 14 ]. Receptor positive  breast cancer refers to a breast malignancy with 
the presence of one or more of the following receptors: oestrogen, progesterone and 
human epidermal growth factor-2 (Table 1). The global incidence of triple-negative 
breast cancer ranges between 10.7-29% of all breast cancers [14-25]. This refers to 
about 200,000 new cases annually [14]. However, Ly et al (2012) reported a higher 
incidence of 46 % in Mali [26]. Triple negative breast cancer is reported to be more 
common in younger women [13, 27-29]. Furthermore, it is more prevalent in black 
women when compared with white women [18,25,28-29].  
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Table 1: Receptor status  
Oestrogen 
receptor  
Positive 
Negative 
Unknown/ not documented on  NHLS histopathological reports 
Progesterone 
receptor 
Positive 
Negative 
Unknown/ not documented on  NHLS histopathological reports 
Her2 receptor Positive 
Negative 
Unknown/ not documented on  NHLS histopathological reports 
 
Triple negative breast cancer is typically more aggressive than other types of breast 
cancer and consequently is associated with a poorer prognosis i.e. a worse five year 
and 10 year overall survival rate [4, 30]. Additionally, TNBC had a higher rate of 
recurrence after treatment [24, 31]. Interestingly, the patients with TNBC are likely to 
have tumour with aggressive markers such as high histopathological grade (Table 2) 
[32]. TNBC is also associated with a higher risk of metastasis [18]. Although there 
are modifications to the Bloom-Richardson Grading System (1957), the National 
Health Laboratory Services histopathological reports had made reference to the 
Bloom-Richardson Grading System (1957), thus this grading system has been 
included in this research report (Table 2). 
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Table 2: The Bloom-Richardson Grading System (1957):  
Grade Points 
Low (Grade I) 3-5 
Intermediate (Grade II) 6-7 
High (Grade III) 8-9 
The next group of breast cancer patients who are expected to fair badly are patients 
who have oestrogen receptor negative tumours [1,2].  Oestrogen receptor negative 
breast cancer patients were found to have a worse outcome than their oestrogen 
receptor positive counterparts [1, 2]. A cancer that is positive for oestrogen and 
progesterone while testing negative for human epidermal growth factor-2; stage for 
stage would be expected to have a better prognosis [33].  
 
Environmental factors associated with poor prognosis in breast cancer patients 
include socioeconomic status, obesity and unhealthy lifestyle [12]. Anaemia impacts 
the prognosis of patients with breast cancer. The European Cancer Anaemia Survey 
described a significant correlation between low haemoglobin level and poor 
performance status in breast cancer patients [34].  
 
Anaemia is defined by the World Health Organization as a haemoglobin level less 
than 12.0 g/dL for non-pregnant women (>15yrs) and less than 11.0 g/dL for 
pregnant women [35]. The global prevalence of anaemia is 24.8% and non pregnant 
women account for 30.2% of the global prevalence [35].  
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Anaemia is classified as macrocytic, normocytic or microcytic [36]. Microcytic 
anaemia refers to a mean corpuscular volume (MCV) less than 82 femtolitres and 
may be due to dietary restrictions such as iron deficiency, thalassemia and anaemia 
of chronic disorders where the cancer interferes with the metabolism and utilisation 
of iron [36]. Normocytic anaemia is defined as a MCV that ranges between 82-98  
femtolitres and may possibly be a result of cytokine medicated inflammatory 
response in cancer. Macrocytic anaemia is defined as a MCV greater than 98 
femtolitres and is commonly associated with vitamin B12 and folate deficiency, 
antiretroviral therapy, chemotherapy and chronic illness such as leukaemia and 
alcoholism [36].  
 
Surgery is the mainstay of treatment of breast cancer [37]. Depending on the stage 
at presentation and histological findings some patients with breast cancer require 
adjuvant or neo-adjuvant chemotherapy and/or radiation [37]. Some patients with 
cancer will present with anaemia that can be detected before, during or after 
treatment [5]. Suggested underlying reasons for anaemia in cancer in general 
include problems in iron metabolism as a result of sequestration of iron by the 
reticulocyte endothelial system, low levels or resistance to erythropoietin and bone 
marrow infiltration [11].  Additionally, patients with breast cancer may already have 
co-morbidities such as diabetes, hypertension, human immunodeficiency virus (HIV) 
[38]. South Africa has a HIV epidemic and many of the  patients are HIV positive and 
may be on Highly Active Antiretroviral Treatment (HAART) [38]. Both HIV and the 
HAART drugs are associated with anaemia [8, 35] which may be due to bone 
marrow failure or infiltration [39].  
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The presence of anaemia in breast cancer patients may delay treatment such as 
mastectomy when Hb<7g/dL or Hb<10g/dL in cardiac or elderly patients [40].  In post 
mastectomy breast cancer patients who are undergoing chemotherapy or radiation 
therapy, anaemia has been implicated as a significant co-factor causing  fatigue [6].  
 
This aim of the study was to evaluate the prevalence and type of anaemia in patients 
with triple negative breast cancer who were managed at the Breast and Endocrine 
Unit at Charlotte Maxeke Johannesburg Academic Hospital. A more detailed 
consideration of the epidemiology of breast cancer will have major health 
implications for risk assessment, prevention; diagnosis, management, healthcare 
resource allocation and policy planning. 
 
Most importantly, the results of this study will contribute to existing knowledge which 
will benefit patient management and improve patient outcomes in the South African 
setting. In addition, this study will provide a baseline for future comparative studies 
within South Africa and Africa.  
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CHAPTER 2 
2. Statistics and Research Methodology 
2.1 Hypothesis 
There is a significant difference in the prevalence and type of anaemia between the 
triple negative receptor breast cancer patients and receptor positive breast cancer 
patients.  
 
2.2 Aim 
To determine the prevalence and type of anaemia in patients with triple negative 
breast cancer at Charlotte Maxeke Johannesburg Academic Hospital.  
 
2.3 Objectives  
1. To study the demography of patients presenting with breast cancer. 
2. To determine the prevalence of triple negative breast cancer. 
3. To determine prevalence and type of anaemia in patients with breast cancer 
and whether this is affected by receptor status. 
 
2.4 Design 
This was a retrospective study.  
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2.5 Setting 
Breast Clinic and Breast and Endocrine Unit at Charlotte Maxeke Johannesburg 
Academic Hospital situated in Parktown, Johannesburg, Republic of South Africa. 
 
2.6 Study Population 
National Health Laboratory Services (NHLS) records of patients diagnosed with 
breast cancer at Charlotte Maxeke Johannesburg Academic Hospital. 
 
2.7 Period 
All NHLS records from January 2002 until December 2012 (11 year period). 
 
2.8 Inclusion and exclusion criteria 
Inclusion criteria was all newly diagnosed breast cancer patients.  
 
The exclusion criteria comprised of patients who: 
• were previously operated at other hospitals. 
• were previously diagnosed with a primary malignancy other than breast 
cancer and presented with a second primary malignancy. 
• presented with recurrence of breast cancer within 2002-2012. These patients 
had an initial mastectomy or wide local excision prior to 2002. 
 
2.9. Ethical Considerations 
This study was approved by the Postgraduate Committee of the University of the 
Witwatersrand and the Human Research Ethics Committee (HREC) of the University 
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of the Witwatersrand - M130439 (Appendix 1). Written permission was obtained from 
the Research Review Board of Charlotte Maxeke Johannesburg Academic Hospital 
and the Head of the Department of Pathology (Professor Hale) at National Health 
Laboratory. This study was conducted at a Master of Medicine (MMED) study level 
with the intention of publication and possible presentation at conferences.  
 
2.10 Data Collection 
Once ethical approval was granted, data was obtained from the National Health 
Laboratory records of all breast cancer patients for the 11 year period of 2002-2012 
at Charlotte Maxeke Johannesburg Academic Hospital. Patient demography, 
histological features and receptor was recorded as well as haemoglobin and mean 
corpuscular volume (Appendix 2). If more than one histopathological report was 
obtained, the initial report i.e. the first report diagnosing breast cancer and a 
matched Hb at the time of diagnosis (within 3 months) of breast cancer was used. If 
multiple Hb level results were retrieved, the one at the time of diagnosis (within 3 
months) of breast cancer was used. 
 
2.11 Data Analysis 
The data was recorded in Excel spreadsheets and the proportion of triple negative 
breast cancer patients with or without anaemia at the time of diagnosis (within 3 
months)  was compared using the chi-squared statistical tests to determine if a 
correlation exists.   Age categories were expressed using the data sets of average 
(including standard deviation) and range. Gender was  calculated as percentages  
and expressed as a ratio.  
 10 
 
 CHAPTER 3 
3. Results 
3.1 Demography 
A total of 520 records were found and based on the exclusion criteria, 94 records 
were excluded for the following reasons (see Figure 1): 
• Four patients were excluded as they were previously operated at other 
hospitals.  
• Fifteen patients were previously diagnosed with a primary malignancy other 
than breast cancer.  
• Sixty one patients presented with recurrence of breast cancer within 2002-
2012. These patients had an initial mastectomy or wide local excision prior to 
2002. 
• Additionally 14 records were excluded as their receptor status was unknown. 
 
The remaining 426 records were further subdivided into TNBC (52 patients) and 
RPBC (374 patients) (see Figure 1). Of these, only 246 patients had a haemoglobin 
level matched at time of diagnosis (within 3 months), that is 29 patients in the TNBC 
group and 217 patients in the RPBC group. Twenty three TNBC patients and 157 
RPBC patients had insufficient data regarding haemoglobin level at time of diagnosis 
(within 3 months). 
Approximately 26% (65/246) of patients with haemoglobin level matched at time of 
diagnosis (within 3 months) had anaemia at the time of presentation. Anaemia at 
time of diagnosis (within 3 months) was found in 55.2% of the TNBC group and 
22.6% of the RPBC group (see Figure 1). 
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Figure 1: Comparison of TNBC and RPBC groups. 
 
 
Sample population for analysis : N= 426 
Triple negative n =52 RPBC group n = 374 
Insufficient 
data 23 
n= 29 
Insufficient 
data 157 
n = 217 
Anaemia 
n= 16 
Normal Hb  
n=12 
Hb> 16.3 
n=1 
Anaemia 
n=49 Normal Hb 
n=160 
Hb> 16.3 
n=8 22.6% 
55.2% 
Exclusion n=80  
4 previously operated 
15 other primary malignancies 
61 recurrence of breast cancer 
14 unknown receptor status 
Total Population: N=  520 
    In the TNBC group, 55.2% had anaemia versus the RPBC group (22.6%). 
    Anaemia was thus more than double in the TNBC group. 
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Table 3: Comparison of age, receptor status and anaemia  
 
 
Parameters 
TNBC n=52 mean +/- 
standard deviation. RPBC n=374 pValue 
Mean Age 
53 ± 11.0 years 
[32-75 years] 
55 ± 13.5 years 
[18-91 years] 0.17 
Hb Average 
11.7 ± 2.4g/dL 
[7.6-16.4g/dL] 
13.2 ± 2.0g/dL 
[7.2-20.3g/dL] 0.0003 
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3.1.1 Age distribution of sample population 
The average age of the sample population (N=374) was 55± 13.3 years (range 18-91 
years).  The average age in the TNBC was 53 ±11.0 years (range 32-75 years) and 
55 ± 13.5 years (range 18-91 years) in the RPBC group (Table 3). The patients in 
the RPBC group presented at a younger age compared to those in the TNBC group. 
Four of the 426 patients had no age recorded on the NHLS database. 
 
3.1.2. Gender distribution  
 
In the sample population of 426 patients, the female : male ratio was 109:1.  The 
distribution was similar among both the TNBC and RPBC groups.  
 
3.2 Histological features of tumour 
 
3.2.1 Histological type of tumour 
Invasive ductal carcinoma was the most common histological type in both TNBC and 
RPBC groups; at 96% and 88% respectively.  
 
3.2.2 Histological grade of tumour 
The grading system was categorised according to the Bloom-Richardson Grading 
System (1957) (Table 2). A high histological grade was more common in the in the 
TNBC group at 71.2 %.  In the RPBC group, moderate histological grade was more 
common at 55.3%. 
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3.3  Receptor status  
Fifty two patients had triple negative breast cancer (TNBC) ie oestrogen, 
progesterone and her 2 receptor negative (Table 4). 
Table 4: Breakdown of breast cancer by receptor status (N=426).   
Receptor 
status 
Oestrogen 
receptor  
Progesterone 
receptor 
Her 2 
receptor 
Number of 
patients 
Percentage 
of sample 
population 
n =426 
 Negative Negative Negative 52 12.2% 
(52/426) 
Positive Positive Positive 95 22.3% 
Positive Positive Negative 138 32.4% 
Positive Negative Positive 28 6.6% 
Negative Positive Positive 2 0.5% 
Positive Negative Negative 35 8.2% 
Negative Positive Negative 11 2.6% 
Negative Negative Positive 52 12.2% 
Negative Negative Unknown 3 0.7% 
Negative Positive Unknown 1 0.2% 
Positive Positive Unknown 8 1.9% 
Positive Negative Unknown 1 0.2% 
Total    426  
 
The remainder of the patients (374) had receptor positive breast cancer (RPBC)  i.e. 
oestrogen and/or progesterone and/or her 2 receptor positive (Table 4). Fourteen of 
the 440 NHLS records that were reviewed has unknown receptor status and were 
thus excluded. 
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3.4  Analysis of haemoglobin results 
3.4.1 Haemoglobin level 
 
Table 5: Haemoglobin distribution of TNBC and RPBC groups  
Hb level g/dL TNBC n=29 (%)  
(44 records were excluded)  
RPBC n=217 (%) 
 (44 records were excluded) 
pValue 
< 10g/dL  8(27.6%) 12(5.6%) 0.0001 
10.1 – 12 g/dL 8(27.6%) 37(17.1%) 0.19 
12.1 – 16.3 
g/dL 
12 (41.4%) 160 (73.6%) 0.0107 
> 16.3 g/dL 1 (3.4%) 8 (3.7%) 0.95 
Total 29 (100%) 217 (100%)  
 
 
The haemoglobin distribution amongst the TNBC and RPBC groups are outlined in 
Table 5. In the TNBC group (52 patients), 31% had a Hb < 12.0; 23% had a normal 
Hb (12.1-16.3), and 2% had a Hb >16.3. In the TNBC group, 44% of Hb levels were 
not found on the NHLS database at the time of diagnosis (within 3 months) of breast 
cancer.  In the RPBC group, 13% had a Hb < 12.0; 41% had a normal Hb (12.1-
16.3), and 2% had a Hb >16.3. In the RPBC group, 44% of Hb levels were not found 
on the NHLS database at the time of diagnosis (within 3 months) of breast cancer.  
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3.4.2 Mean corpuscular volume and types of anaemia  
Table 6: Mean Corpuscular Volume distribution of TNBC and RPBC anaemic 
patients. 
TNBC number 
of patients with 
anaemia n =16 
MICROCYTIC 
Anaemia  
MCV <82  
Femtolitres 
NORMOCYTIC 
Anaemia  
MCV 82 - 98 
femtolitres 
MACROCYTIC 
Anaemia  
MCV >98 femtolitres 
 
Total 7 7 2 
Percentage 43,75% 43,75% 12.5% 
RPBC number 
of patients with 
anaemia n =49 
MICROCYTIC 
Anaemia  
MCV <82  
Femtolitres 
NORMOCYTIC 
Anaemia  
MCV 82 - 98 
femtolitres 
MACROCYTIC 
Anaemia  
MCV >98 femtolitres 
 
Total 22 25 2 
Percentage 44,89% 51.02% 0.4% 
 
 
In the TNBC group (see Table 6), 16 of 29 patients had anaemia and microcytic and 
normocytic anaemia were equally common 43,8% (7/16 patients).  In the RPBC 
group (see Table 6),  49 of 217 patients had anaemia; normocytic anaemia was the 
most common i.e. 51% (25/49 patients).  
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CHAPTER 4 
4. Discussion 
The main finding of this study is that anaemia is more prevalent and more significant 
(i.e. Hb < 10g/dL) in TNBC patients compared to RPBC patients. Interestingly, 
microcytic and normocytic anaemia were equally common in the TNBC patients.  
 
4.1  Demography 
Majority of patients were female (99%) with a female: male ratio was 109:1. This is  
in keeping with global trends [41]. The distribution was similar among both the TNBC 
and RPBC groups. 
 
In the general population, the age of onset of breast cancer in 95% of new cases 
occurred in women 40 years or older [41]. The mean age of the study group (N=426) 
was 55 years; this is similar to the data recorded in another study recently performed 
at Chris Hani Baragwanath Hospital where the mean age of population was 55 years 
[42]. The mean age in the TNBC group and RPBC group were 53 years and 55 
years respectively. TNBC is reported in studies to be a disease of young women and 
it is of interest that the TNBC patients in this study were middle-aged [13, 27-29]. 
Furthermore, there was no statistically significant difference in age at presentation 
between the TNBC and RPBC groups. 
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A recent study performed in Soweto, reported a rate of HIV probability of 19.7 % in 
breast cancer and HIV status was not associated with stage of tumour or molecular 
subtype i.e. receptor status [39]. Murugan et al, revealed that 90% of patients in their 
general study population were black [42]. International studies have shown that 
TNBC is more common in black women when compared with white women [18, 25, 
28-29]. As the current study was a retrospective review of NHLS histopathological 
reports, information regarding race and HIV status was missing in the majority of the 
reports. It was therefore not included for data analysis.  
 
4.2  Histological type and grade 
Invasive ductal carcinoma was the most common histological subtype in both TNBC 
and other group; at 96% and 88% respectively. In the sample population (N=426), 
other histological subtypes were ductal carcinoma in situ (4.7%), invasive lobular 
carcinoma (3.6%), mixed invasive lobular and ductal carcinoma (4.7%). Interestingly, 
the incidence of invasive lobular carcinoma was lower than that reported in the 
literature [43]. A high histological grade was more common in the in the TNBC group 
at 71.2 % which is in keeping with the current literature [17].  
 
Although the poor prognostic factors of TNBC include lymphovascular invasion [17], 
information in the current study was incomplete in the majority of NHLS records. It 
would be of interest to assess the differences of lymphovascular invasion in the 
TNBC and RPBC groups. 
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4.3 Receptor status 
In this study, the prevalence of TNBC was 12.2% which is significantly lower that 
reported in two South African studies by Cubash et al and Murugan et al who 
reported a prevalence of 21.5% and 20.7 % respectively [38, 42].  
 
4.4 Anaemia and breast cancer          
Anaemia is defined by the World Health Organization as a haemoglobin level less 
than 12.0 g/dL for non-pregnant women (>15yrs) and less than 11.0 g/dL for 
pregnant women [35]. The global prevalence of anaemia is 24.8% and non pregnant 
women account for 30.2% of the global prevalence [35].  
 
In the study population, approximately 26.0% (65/246) of patients with haemoglobin 
level matched at time of diagnosis (within 3 months) had anaemia at the time of 
presentation. Anaemia was found to be more significant and prevalent in the TNBC 
group as 55.2% of the TNBC group had anaemia whereas 22.6% of the RPBC group 
patients were found to have anaemia at presentation. 
 
Some patients with breast cancer may already have co-morbidities such as diabetes, 
hypertension, human immunodeficiency virus (HIV) [38]. South Africa has a HIV 
epidemic and many of the patients are HIV positive and may be on Highly Active 
Antiretroviral Treatment (HAART) [38]. Both HIV and the HAART drugs are 
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associated with anaemia [8, 35].  It may be due to bone marrow failure or infiltration; 
and may be chronic and severe [39].  
 
Although iron studies were not done in this study, it is possible that poor dietary 
intake as seen in patients from poor social economic backgrounds; and possible  
influence of cancer on bone marrow metabolism may be contributing factors towards 
iron deficiency anaemia [44, 45]. It is thus evident that anaemia may be 
multifactorial. A prospective study is thus recommended in order to determine the 
cause of anaemia in study population. 
 
 
The European Cancer Anaemia Survey (ECAS) has demonstrated that in patients 
with various cancer types, 39% had anaemia at enrolment and 68% developed 
anaemia during the 6 month survey period [46]. Anaemia has been reported to occur 
in breast cancer patients [5] and some patients with cancer will present similar to 
patients with anaemia of chronic disease [5]. Anaemia in cancer can be detected 
before, during or after treatment [5]. Some of the suggested underlying reasons for 
anaemia in cancer are problems in iron metabolism such as sequestration of iron by 
the reticulocyte endothelial system, low levels or resistance to erythropoietin and 
bone marrow infiltration [11].   
 
Surgery is the mainstay of treatment of breast cancer [37] . Depending on the stage 
at presentation and histological findings some patients with breast cancer will require 
adjuvant or neo-adjuvant chemotherapy and/or radiation [37]. Surgery is the 
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mainstay of treatment and some patients may require adjuvant or neo-adjuvant 
chemotherapy and radiation [37]. The presence of anaemia in breast cancer patients 
may delay treatment such as mastectomy when Hb<7g/dL in fit patients or 
Hb<10g/dL in cardiac or elderly patients [40].  
 
Patients with TNBC as compared to the RPBC group are likely to present with 
significant anaemia, that is Hb level <10g/dL. These patients would either require 
pre-intervention blood transfusion or risk worsening of anaemia post chemotherapy 
which is essential in the management of TNBC patients [47]. There is evidence that 
the pre-treatment state of a cancer patient may impair that patient’s response to 
chemotherapy [10]. Anaemia is one of the risk factors known to decrease the 
response to chemotherapy [10].  Additionally, anaemia has been implicated in poor 
wound healing and dehiscence [48].  
 
Anaemia is classified as macrocytic, normocytic or microcytic [36]. Microcytic 
anaemia refers to a mean corpuscular volume (MCV) less than 82 femtolitres and 
may be due to dietary restrictions such as iron deficiency, thalassemia and anaemia 
of chronic disorders where the cancer interferes with the metabolism and utilisation 
of iron [36]. Normocytic anaemia is defined as a MCV that ranges between 82-98  
femtolitres and may possibly be a result of cytokine medicated inflammatory 
response in cancer. Macrocytic anaemia is defined as a MCV greater than 98 
femtolitres and is commonly associated with vitamin B12 and folate deficiency, 
antiretroviral therapy, chemotherapy and chronic illness such as leukaemia and 
alcoholism [36].  
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In the TNBC group, 16 of 29 patients had anaemia and microcytic and normocytic 
anaemia were equally common. In the RPBC group, 49 of 217 patients had anaemia 
and normocytic anaemia was the most common (51.0%). A prospective study is thus 
recommended to determine the cause of anaemia and the type of anaemia.  
 
 
A fundamental principle in breast cancer is that cytokines may cause an 
inflammatory process that causes inflammatory induced anaemia. Cytokine 
impairment of erythropoietin occurs as a result of the inflammatory process where 
Tumour Necrosis Factor α, Interleukin-1 and Interleukin-6 are released. Tumour 
Necrosis Factor α results in reduced lifespan of the red blood cell. Tumour Necrosis 
Factor α and Interleukin-1 impair erythropoietin production by the kidney. Interleukin-
6 worsens anaemia by plasma volume expansion and increases hepcidin secretion 
which inhibits iron absorption and release from macrophages [11]. Knowledge of the 
cytokine profile of TNBC may assist in the understanding as to why TNBC is known 
to be aggressive and have a worse prognosis. This may form a basis for further 
studies where targeted molecular therapy maybe be developed to dampen or stop 
the cytokine inflammatory process which has been postulated to cause anaemia.  
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4.5 Impact of anaemia on the outcome of other cancers 
Anaemia is common in patients with right sided colon cancer [49]. The presence of 
anaemia in at risk patients alerts clinicians to the possibility of colorectal cancer [49]. 
However, colorectal cancer patients who receive blood transfusions have worse 
outcomes [49]. Peri-operative blood transfusion was associated with an increased 
relative risk of death [49]. Transfusion trigger protocols advocate transfusing patients 
whose hemoglobin level is less than 7g/dL or 10g/dL in cardiac patients [40]. Breast 
cancer patients commonly have anaemia of chronic disease secondary to the 
disease itself or bone marrow infiltration [39]. These patients may require blood 
transfusion pre-operatively or before chemotherapy and this may delay treatment 
and may also be prone to developing anaemia after chemotherapy.  
 
4.6 Limitations 
The limitations of the study were as a result of the unavailability and quality of the 
NHLS records, many of which were incomplete. The lack of categorising of patients 
into racial groups makes it difficult to analyse the results. Majority of the patients in 
the study did not have any record of an HIV test result on the NHLS database, that is 
82% patients in the triple negative breast cancer group and 86.59% patients in the 
other group. The lack of this information made it impossible to comment on any 
correlations between TNBC and HIV status or race. Additionally, information on other 
co-morbidities were not available on the NHLS database.  
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The haemoglobin level that was used was found on the NHLS database at the time 
of the initial diagnosis. This means that the matched haemoglobin was done at the 
time of diagnosis (within 3 months) of breast cancer. If there was no Hb level done at 
the time of diagnosis (within 3 months), this was categorised as insufficient or 
inadequate data and was not included in the calculation of the type and prevalence 
of anaemia. 
  
The reason for excluding the Hb level if it was not done at the time of diagnosis 
(within 3 months)  is that the patient may have been exposed to chemotherapy, 
radiotherapy or surgical procedures. This was a retrospective study and the 
histopathological results together with the haemoglobin level at the time of diagnosis 
(within 3 months) were obtained. It must be acknowledged that the histopathological 
reports may not have a fully comprehensible history. It is  acknowledged that factors 
such as chemotherapy, radiotherapy or surgical procedures may influence the Hb 
level.  In this study, it was assumed that chemotherapy would only be started once 
the diagnosis was confirmed on histology. This study involves reviewing patients on 
their first presentation and a matched Hb level at this time. Twenty three patients in 
the TNBC group and 157 patients in RPBC had insufficient data and these records 
were removed from the calculation of the type and prevalence of anaemia. After 
removing these patients, 16 of 29 of TNBC group patients had anaemia that is -
55,2% and 49 of 217 of other group had anaemia that is 22,6%.  
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4.7 Risk of Bias  
This is a a very small subset of patients, those who came directly to the Breast Clinic 
and Breast and Endocrine Unit at Charlotte Maxeke Johannesburg Academic 
Hospital as a first presentation where their cancer was diagnosed and a 
haemoglobin level was done at that time.  Patients who first went to other hospitals 
and were  referred to CMJAH Breast Clinic were excluded.  
The records were accessed through the NHLS database using a programme called 
“Snomed” which created a list of all breast specimen samples that were examined at 
the NHLS between January 2002 – December 2012 (11 year period). Only, the 
histopathological reports of those specimens that came from Breast Clinic and 
Breast and Endocrine Unit at Charlotte Maxeke Johannesburg Academic Hospital 
were then examined. If duplicate samples were encountered, for example a core 
biopsy and a mastectomy sample for the same patient, the initial core biopsy was 
used. This amounted to 520 histopathological reports, of which 80 reports were 
excluded based on the exclusion criteria. Additionally, fourteen records were 
excluded as the receptor status was unknown. 
 
The number of patients used to calculate the prevalence and type of anaemia was 
even smaller due to missing data and records that did not have a matched Hb level 
at the time of diagnosis (within 3 months)  of breast cancer. Thus the sample size 
was reduced to 246 patients when those who did not have a matched Hb level at the 
time of diagnosis (within 3 months) of breast cancer were further eliminated. Thus a 
selection bias due to incomplete reporting data may be present. 
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CHAPTER 5 
5. Conclusion 
 
In conclusion, the main findings of this study are: 
1. More than 50% of the TNBC patients were anaemic when diagnosed with 
breast cancer. 
2. The prevalence of anaemia in the TNBC patients was greater than that of the 
RPBC patients. 
3. The anaemia in the TNBC patients was more likely to be clinically significant 
(Hb <10g/dL) than that of the RPBC patients. 
4. The predominant types of anaemia found in TNBC patients are microcytic and 
normocytic and may suggest different mechanisms. Within the TNBC group, 
microcytic and normocytic and macrocytic anaemia were 7/16 (43.75%); 7/16 
(43.75%); and 2/16 (12,5%) respectively.  
5. Within the RPBC group, microcytic and normocytic and macrocytic anaemia 
were 22(44,89%); 25 (51.02%) and 2 (0.4%) respectively.  
 
Correcting anaemia before any treatment of breast cancer is commenced is likely 
to improve the response to and the outcome of that treatment. This may be of 
particular importance in patients suffering from the more aggressive types of 
breast cancer.  
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6. CHAPTER 6 
6.1 Recommendations  
6.1.1. Implications for practice  
It is recommended that a routine Hb level and MCV to be done at the time of initial 
diagnosis of breast cancer. If microcytic anaemia is present, iron studies have to be 
performed. Anaemia should be corrected prior to chemotherapy or surgery.   
 
6.2. Implications for research  
The study provides a stimulus to undertake other comparative studies of iron status 
and iron deficiency in breast cancer patients in South Africa and Africa. A 
prospective study of prevalence and causes of pre-treatment anaemia in breast 
cancer is indicated. 
 
Knowledge of the cytokine profile of TNBC may assist in the understanding as to 
why TNBC is known to be aggressive and have a worse prognosis. This may form a 
basis for further studies where targeted molecular therapy maybe be developed to 
dampen or stop the cytokine inflammatory process which has been postulated to 
cause anaemia. 
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Appendix 2: Data collection sheet 
 
Patient series number    ____________ 
Demographics 
Age  
Race  
Gender  
HIV status CD4 count 
 
Staging, Histological subtype and Profile 
Stage:  1 2 3 4 
Nodal involvement  Yes No 
Metastatic disease Yes. Site: 
 
No 
Histological subtype Ductal 
carcinoma in 
situ 
Ductal 
carcinoma 
Lobular 
carcinoma 
Others: 
________________ 
Oestrogen Positive  Negative  
Progesterone Positive  Negative  
Her2 Receptor Positive Negative  
Histological grade 
differentation 
Low Intermediate/Moderate High 
Lymphovascular 
invasion 
Yes No  
 
Date Haemoglobin  Mean Corpuscular Volume 
   
   
 
 
